311 related articles for article (PubMed ID: 30528263)
1. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.
Erpicum P; Weekers L; Detry O; Bonvoisin C; Delbouille MH; Grégoire C; Baudoux E; Briquet A; Lechanteur C; Maggipinto G; Somja J; Pottel H; Baron F; Jouret F; Beguin Y
Kidney Int; 2019 Mar; 95(3):693-707. PubMed ID: 30528263
[TBL] [Abstract][Full Text] [Related]
2. Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.
Detry O; Vandermeulen M; Delbouille MH; Somja J; Bletard N; Briquet A; Lechanteur C; Giet O; Baudoux E; Hannon M; Baron F; Beguin Y
J Hepatol; 2017 Jul; 67(1):47-55. PubMed ID: 28284916
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection After Kidney Transplantation- A Single-Arm, Two-Dosing-Regimen, Phase I/II Study.
Wei Y; Chen X; Zhang H; Su Q; Peng Y; Fu Q; Li J; Gao Y; Li X; Yang S; Ye Q; Huang H; Deng R; Li G; Xu B; Wu C; Wang J; Zhang X; Su X; Liu L; Xiang AP; Wang C
Front Immunol; 2021; 12():662441. PubMed ID: 34248942
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
5. Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation.
Lohan P; Murphy N; Treacy O; Lynch K; Morcos M; Chen B; Ryan AE; Griffin MD; Ritter T
Front Immunol; 2018; 9():2666. PubMed ID: 30515159
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells in renal transplantation: opportunities and challenges.
Casiraghi F; Perico N; Cortinovis M; Remuzzi G
Nat Rev Nephrol; 2016 Apr; 12(4):241-53. PubMed ID: 26853275
[TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.
Perico N; Casiraghi F; Gotti E; Introna M; Todeschini M; Cavinato RA; Capelli C; Rambaldi A; Cassis P; Rizzo P; Cortinovis M; Noris M; Remuzzi G
Transpl Int; 2013 Sep; 26(9):867-78. PubMed ID: 23738760
[TBL] [Abstract][Full Text] [Related]
8. Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study.
Reinders ME; de Fijter JW; Roelofs H; Bajema IM; de Vries DK; Schaapherder AF; Claas FH; van Miert PP; Roelen DL; van Kooten C; Fibbe WE; Rabelink TJ
Stem Cells Transl Med; 2013 Feb; 2(2):107-11. PubMed ID: 23349326
[TBL] [Abstract][Full Text] [Related]
9. Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.
Casiraghi F; Todeschini M; Azzollini N; Cravedi P; Cassis P; Solini S; Fiori S; Rota C; Karachi A; Carrara C; Noris M; Perico N; Remuzzi G
Transplantation; 2019 Jun; 103(6):1121-1130. PubMed ID: 30801518
[TBL] [Abstract][Full Text] [Related]
10. Marrow Mesenchymal Stem Cells Effectively Reduce Histologic Changes in a Rat Model of Chronic Renal Allograft Rejection.
Yu P; Wang Z; Liu Y; Xiao Z; Guo Y; Li M; Zhao M
Transplant Proc; 2017 Nov; 49(9):2194-2203. PubMed ID: 29149982
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial.
Sun Q; Huang Z; Han F; Zhao M; Cao R; Zhao D; Hong L; Na N; Li H; Miao B; Hu J; Meng F; Peng Y; Sun Q
J Transl Med; 2018 Mar; 16(1):52. PubMed ID: 29514693
[TBL] [Abstract][Full Text] [Related]
12. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility.
Perico N; Casiraghi F; Introna M; Gotti E; Todeschini M; Cavinato RA; Capelli C; Rambaldi A; Cassis P; Rizzo P; Cortinovis M; Marasà M; Golay J; Noris M; Remuzzi G
Clin J Am Soc Nephrol; 2011 Feb; 6(2):412-22. PubMed ID: 20930086
[TBL] [Abstract][Full Text] [Related]
13. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
Reinders ME; Dreyer GJ; Bank JR; Roelofs H; Heidt S; Roelen DL; Zandvliet ML; Huurman VA; Fibbe WE; van Kooten C; Claas FH; Rabelink TJ; de Fijter JW
J Transl Med; 2015 Nov; 13():344. PubMed ID: 26537851
[TBL] [Abstract][Full Text] [Related]
14. Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors.
Schachtner T; Stein M; Reinke P
Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28296035
[TBL] [Abstract][Full Text] [Related]
15. A Large-Scale Bank of Organ Donor Bone Marrow and Matched Mesenchymal Stem Cells for Promoting Immunomodulation and Transplant Tolerance.
Johnstone BH; Messner F; Brandacher G; Woods EJ
Front Immunol; 2021; 12():622604. PubMed ID: 33732244
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection.
Shi M; Liu Z; Wang Y; Xu R; Sun Y; Zhang M; Yu X; Wang H; Meng L; Su H; Jin L; Wang FS
Stem Cells Transl Med; 2017 Dec; 6(12):2053-2061. PubMed ID: 29178564
[TBL] [Abstract][Full Text] [Related]
17. TGF-β1-Licensed Murine MSCs Show Superior Therapeutic Efficacy in Modulating Corneal Allograft Immune Rejection In Vivo.
Lynch K; Treacy O; Chen X; Murphy N; Lohan P; Islam MN; Donohoe E; Griffin MD; Watson L; McLoughlin S; O'Malley G; Ryan AE; Ritter T
Mol Ther; 2020 Sep; 28(9):2023-2043. PubMed ID: 32531237
[TBL] [Abstract][Full Text] [Related]
18. Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function.
Cherukuri A; Salama AD; Carter CR; Landsittel D; Arumugakani G; Clark B; Rothstein DM; Baker RJ
Kidney Int; 2017 Jan; 91(1):183-195. PubMed ID: 28029430
[TBL] [Abstract][Full Text] [Related]
19. Infusion of Allogeneic Mesenchymal Stromal Cells After Liver Transplantation: A 5-Year Follow-Up.
Vandermeulen M; Mohamed-Wais M; Erpicum P; Delbouille MH; Lechanteur C; Briquet A; Maggipinto G; Jouret F; Beguin Y; Detry O
Liver Transpl; 2022 Apr; 28(4):636-646. PubMed ID: 34605167
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.
Mielcarek M; Storb R; Georges GE; Golubev L; Nikitine A; Hwang B; Nash RA; Torok-Storb B
Biol Blood Marrow Transplant; 2011 Feb; 17(2):214-25. PubMed ID: 20816818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
